ArticleCancer immunology research2022
NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer immunology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis.Frontiers in immunology · 2022Pooled it
- Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.Nature communications · 2024Trial
- Exploring the functions of NKG7 in CD4+ and CD8+ T cells during malaria.PLoS pathogens · 2026Article
- Gamma Delta T Cells in Shrimp Allergy Express a Unique Cytotoxic Cytokine Profile.Clinical and translational allergy · 2026Article
- Informing agent-based models with spatial data using convolutional autoencoders.Bioinformatics (Oxford, England) · 2026Article
- Unraveling the regulatory role of intercellular communication in intestinal immune cells mediated by H₂ in sepsis recovery through single-cell RNA sequencing.Journal of translational medicine · 2026Article
- Inflammatory arthritis irAE may represent a unique autoimmune disease primarily driven by T cells but likely not autoantibodies.Science advances · 2026Article
- CUL5 E3 ubiquitin ligase regulates the evasion of bladder cancer cells to CD8+ T cell-mediated killing by inhibiting autophagy.PLoS biology · 2026Article
- NR4A1 limits CD8Research square · 2026Article
- NR4A1 limits CD8⁺ T Cell effector responses and protection in tuberculosis.bioRxiv : the preprint server for biology · 2026Article
- Combining local cytokine delivery and systemic immunization with recombinant artLCMV boosts antitumor efficacy in several preclinical tumor models.Oncoimmunology · 2025Article
- A Dual Role for NKG7 in T-cell Cytotoxicity and Longevity.Cancer immunology research · 2025Review
- Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies.medRxiv : the preprint server for health sciences · 2025Article
- Identification of immunosuppressive CD4Discover oncology · 2025Article
- Article
- Article
- Natural killer cell granule protein 7 contributes to CD8Research and practice in thrombosis and haemostasis · 2025Article
- Enhancing thymic function improves T-cell reconstitution and immune responses in aged mice.PLoS biology · 2025Article
- NKG7 is a Stable Marker of Cytotoxicity Across Immune Contexts and Within the Tumor Microenvironment.European journal of immunology · 2025Article
- Characterizing the immune landscape of tumor-infiltrating lymphocytes in non-small cell lung cancer.Genes and immunity · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 2 institutions in 1 country.
Ti Wen *Department of Urology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-6688-211X
Whitney Barham *Department of Immunology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
Ying Li *Division of Computational Biology, Mayo Clinic, Rochester, Minnesota.
Henan ZhangDepartment of Urology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-5680-4687
Joanina K GicobiDepartment of Immunology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
Jacob B HirdlerDepartment of Urology, Mayo Clinic, Rochester, Minnesota.
Xin LiuDepartment of Urology, Mayo Clinic, Rochester, Minnesota.
Hyoungjun HamDepartment of Immunology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
Kodi E Peterson MartinezDepartment of Immunology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
Fabrice LucienDepartment of Urology, Mayo Clinic, Rochester, Minnesota.
Roxane R LavoieDepartment of Urology, Mayo Clinic, Rochester, Minnesota.
Hu LiCenter for Individualized Medicine, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
Cristina CorreiaCenter for Individualized Medicine, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.ORCID 0000-0002-9464-7555
Dileep D MonieDepartment of Immunology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.ORCID 0000-0001-6782-2613
Zesheng AnDepartment of Urology, Mayo Clinic, Rochester, Minnesota.
Susan M HarringtonDepartment of Urology, Mayo Clinic, Rochester, Minnesota.
Xiaosheng WuDivision of Hematology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
Ruifeng GuoDepartment of Laboratory Medicine and Pathology, Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota.
Roxana S DroncaDivision of Medical Oncology, Mayo Clinic, Jacksonville, Florida.
Aaron S MansfieldDivision of Medical Oncology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-9483-6903
Yiyi YanDivision of Medical Oncology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0001-8981-4702
Svetomir N MarkovicDivision of Medical Oncology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-9238-4325
Sean S ParkDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0003-3814-853X
Jie SunDepartment of Immunology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
Hong QinDivision of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida.
Minetta C LiuDivision of Medical Oncology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-8206-5232
George VasmatzisDepartment of Molecular Medicine, Mayo Clinic, Rochester, Minnesota.
Daniel D BilladeauDepartment of Immunology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.ORCID 0000-0002-2296-9547
Haidong DongDepartment of Urology, Mayo Clinic, Rochester, Minnesota. dong.haidong@mayo.edu.ORCID 0000-0002-5782-2983
Mayo Clinic · USJacksonville College · US
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3MPaul Calabresi Program in Clinical/Translational Research at Mayo ClinicK12CA090628 · NCI · MAYO CLINIC ROCHESTER · PI WEROHA, SARAVUT · 2001 to 2025
$19.7MMedical Scientist Traning Program at Mayo ClinicT32GM065841 · NIGMS · MAYO CLINIC ROCHESTER · PI KAUFMANN, SCOTT H, SCHIMMENTI, LISA A · 2003 to 2022
$5.8MFunctional B7-H1 expressed by T cellsR01AI095239 · NIAID · MAYO CLINIC ROCHESTER · PI DONG, HAIDONG · 2014 to 2018
$2.0MTargeting dual functions of PD-L1 for cancer therapyR01CA256927 · NCI · MAYO CLINIC ROCHESTER · PI DONG, HAIDONG · 2021 to 2025
$1.8MA Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABRR01CA200551 · NCI · MAYO CLINIC ROCHESTER · PI DONG, HAIDONG, PARK, SEAN S · 2016 to 2018
$739kBlood-based biomarker of therapeutic efficacy for mesotheliomaR21CA251923 · NCI · MAYO CLINIC ROCHESTER · PI MANSFIELD, AARON SCOTT · 2020 to 2020
$409kRole of Bim and soluble B7-H1 in monitoring T cell responses to anti-PD-1 therapy in melanomaR21CA197878 · NCI · MAYO CLINIC ROCHESTER · PI DONG, HAIDONG, DRONCA, ROXANA S · 2015 to 2016
$374kIncreasing the cytotoxicity of T cells in response to PD-1 blockadeF30CA250326 · NCI · MAYO CLINIC ROCHESTER · PI BARHAM, WHITNEY · 2020 to 2022
$141kNetwork mechanisms and bioengineering of precision immunotherapies for glioblastomasF30CA250122 · NCI · MAYO CLINIC ROCHESTER · PI MONIE, DILEEP DANIEL · 2021 to 2023
$125kNCI NIH HHS F30 CA250122NCI NIH HHS F30 CA250326NCI NIH HHS K12 CA090628NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA200551NCI NIH HHS R01 CA256927NCI NIH HHS R21 CA197878NCI NIH HHS R21 CA251923NIAID NIH HHS R01 AI095239NIGMS NIH HHS T32 GM065841
Abstract
Cytotoxic CD8
Indexed as
CD8-Positive T-LymphocytesImmunotherapyMembrane ProteinsNeoplasmsRNA, MessengerAnimalsHumansMiceT-Lymphocytes, CytotoxicMembrane ProteinsNKG7 protein, humanNkg7 protein, mouseRNA, Messenger
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.